Corcept Therapeutics Incorporated Company Profile (NASDAQ:CORT)

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated logoCorcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company's focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). It has also discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. It has begun pre-clinical and clinical development of its lead compounds from these series.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: CORT
  • CUSIP: 21835210
Key Metrics:
  • Previous Close: $8.30
  • 50 Day Moving Average: $7.796
  • 200 Day Moving Average: $7.202
  • 52-Week Range: $3.52 - $10.00
  • Trailing P/E Ratio: 212.692
  • Foreward P/E Ratio: 37.70
  • P/E Growth: -1.050
  • Market Cap: $921.00M
  • Outstanding Shares: 111,031,000
  • Beta: 1.72
Profitability:
  • Net Margins: 6.21%
  • Return on Equity: 28.11%
  • Return on Assets: 11.96%
Debt:
  • Current Ratio: 1.89%
  • Quick Ratio: 1.81%
Additional Links:
Companies Related to Corcept Therapeutics Incorporated:

Analyst Ratings

Consensus Ratings for Corcept Therapeutics Incorporated (NASDAQ:CORT) (?)
Ratings Breakdown: 1 Sell Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $11.25 (35.62% upside)

Analysts' Ratings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Show:
DateFirmActionRatingPrice TargetDetails
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$14.00View Rating Details
12/20/2016Janney Montgomery ScottInitiated CoverageSell$7.00View Rating Details
11/2/2016FBR & CoSet Price TargetBuy$12.00View Rating Details
10/19/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
5/3/2016Q116$0.01$0.02$16.32 million$16.10 millionViewN/AView Earnings Details
1/28/2016Q415($0.02)$0.01$15.50 million$15.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.02)($0.01)$13.90 million$13.30 millionViewN/AView Earnings Details
8/5/2015Q215($0.04)($0.02)$11.67 million$11.96 millionViewN/AView Earnings Details
5/7/2015Q115($0.04)($0.05)$10.50 million$10.10 millionViewN/AView Earnings Details
3/4/2015Q414($0.06)($0.02)$9.10 million$9.01 millionViewN/AView Earnings Details
11/4/2014Q214($0.07)($0.06)$7.62 million$7.28 millionViewN/AView Earnings Details
8/5/2014Q2($0.10)($0.05)$6.00 million$5.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.09)($0.11)$5.01 million$4.41 millionViewN/AView Earnings Details
3/5/2014Q413($0.10)($0.11)$4.01 million$4.10 millionViewN/AView Earnings Details
1/30/2014Q4($0.12)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$2.70 million$2.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.10)$2.72 million$1.90 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$2.48 million$1.72 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.09)($0.09)$1.50 million$1.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Current Year EPS Consensus Estimate: $0.070 EPS
Next Year EPS Consensus Estimate: $0.220 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.01$0.01$0.01
Q2 20161$0.02$0.02$0.02
Q3 20161$0.03$0.03$0.03
Q4 20161$0.03$0.03$0.03
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 43.57%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/25/2016Patrick G EnrightDirectorSell36,941$9.34$345,028.94View SEC Filing  
11/21/2016Patrick G EnrightDirectorSell544,100$9.56$5,201,596.00View SEC Filing  
11/16/2016Patrick G EnrightDirectorSell174,847$9.55$1,669,788.85View SEC Filing  
11/11/2016James N WilsonDirectorSell158,812$8.51$1,351,490.12View SEC Filing  
11/11/2016Joseph K BelanoffInsiderSell500,000$8.98$4,490,000.00View SEC Filing  
11/7/2016Joseph K BelanoffCEOSell500,000$8.31$4,155,000.00View SEC Filing  
5/10/2016G Leonard Baker JrDirectorBuy100,000$4.88$488,000.00View SEC Filing  
1/6/2016James N WilsonDirectorSell1,188$4.90$5,821.20View SEC Filing  
12/10/2015Daniel BradburyDirectorSell20,000$4.85$97,000.00View SEC Filing  
11/24/2015Daniel BradburyDirectorSell40,000$5.00$200,000.00View SEC Filing  
11/12/2015James N WilsonDirectorSell20,000$4.90$98,000.00View SEC Filing  
11/2/2015Steven LoVPSell12,500$4.00$50,000.00View SEC Filing  
10/13/2015Steven LoVPSell53,033$3.82$202,586.06View SEC Filing  
10/7/2015Steven LoVPSell5,300$4.00$21,200.00View SEC Filing  
10/6/2015Steven LoVPSell50,000$3.76$188,000.00View SEC Filing  
9/16/2015Daniel BradburyDirectorSell20,000$4.96$99,200.00View SEC Filing  
9/1/2015James N WilsonDirectorSell10,000$4.90$49,000.00View SEC Filing  
8/27/2015Daniel BradburyDirectorSell20,000$4.76$95,200.00View SEC Filing  
7/21/2015Daniel BradburyDirectorSell10,000$4.98$49,800.00View SEC Filing  
7/20/2015Daniel BradburyDirectorSell10,000$5.32$53,200.00View SEC Filing  
7/8/2015David L MahoneyDirectorSell33,828$5.74$194,172.72View SEC Filing  
7/1/2015James N WilsonDirectorSell10,000$6.06$60,600.00View SEC Filing  
6/24/2015Daniel BradburyDirectorSell20,000$6.75$135,000.00View SEC Filing  
6/23/2015Daniel BradburyDirectorSell10,000$6.92$69,200.00View SEC Filing  
6/2/2015James N WilsonDirectorSell10,000$6.13$61,300.00View SEC Filing  
3/24/2015Patrick G EnrightDirectorSell1,089,745$5.75$6,266,033.75View SEC Filing  
3/19/2015Joseph C Cook JrDirectorSell77,200$5.22$402,984.00View SEC Filing  
6/11/2014G Leonard Baker JrDirectorBuy103,386$2.32$239,855.52View SEC Filing  
5/13/2014Joseph Cook, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/12/2014Daniel BradburyDirectorBuy138,925$1.80$250,065.00View SEC Filing  
5/9/2014G Leonard Baker, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/2/2014Longitude Venture Partners L.PDirectorSell250,000$4.11$1,027,500.00View SEC Filing  
4/1/2014Patrick EnrightDirectorSell250,000$4.28$1,070,000.00View SEC Filing  
3/7/2014Longitude Venture Partners L.PDirectorSell250,000$4.00$1,000,000.00View SEC Filing  
3/14/2013Joseph L TurnerDirectorBuy10,000$2.01$20,100.00View SEC Filing  
12/5/2012G Leonard Baker JrDirectorBuy87,131$1.46$127,211.26View SEC Filing  
11/23/2012Daniel BradburyDirectorBuy179,000$1.39$248,810.00View SEC Filing  
11/7/2012G Leonard Baker JrDirectorBuy300,000$1.83$549,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Corcept Therapeutics Incorporated (NASDAQ:CORT)
DateHeadline
News IconMarket Update on Shares of Corcept Therapeutics Incorporated (CORT) - BVN (NASDAQ:CORT)
bvnewsjournal.com - February 17 at 3:36 PM
marketexclusive.com logoCorcept Therapeutics Incorporated (NASDAQ:CORT) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (NASDAQ:CORT)
marketexclusive.com - February 14 at 10:17 PM
News IconStock Spotlight: Zooming in on Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Piedmont Register (NASDAQ:CORT)
piedmontregister.com - February 14 at 5:14 PM
capitalcube.com logoCorcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : February 14, 2017 (NASDAQ:CORT)
www.capitalcube.com - February 14 at 5:14 PM
biz.yahoo.com logoCORCEPT THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financi (NASDAQ:CORT)
biz.yahoo.com - February 13 at 5:06 PM
benzinga.com logoLadenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy - Benzinga (NASDAQ:CORT)
www.benzinga.com - February 2 at 9:52 PM
finance.yahoo.com logoCoverage initiated on Corcept Therapeutics by Ladenburg Thalmann (NASDAQ:CORT)
finance.yahoo.com - February 2 at 4:49 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Corcept Therapeutics Incorporated (NASDAQ:CORT)? - Wall Street Beacon (NASDAQ:CORT)
wsbeacon.com - January 31 at 4:54 PM
News IconAvēsis Incorporated Company Profile (NASDAQ:CORT)
www.bioportfolio.com - January 31 at 4:54 PM
finance.yahoo.com logoEdited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT (NASDAQ:CORT)
finance.yahoo.com - January 31 at 4:54 PM
News IconCorcept Therapeutics (NASDAQ:CORT) 4Q16 earnings; Beats Street View (NASDAQ:CORT)
stockmarketdaily.co - January 31 at 3:18 AM
News IconCorcept Therapeutics Incorporated (NASDAQ:CORT) to Post $0.02 Earnings Per Share: Analysts - Wall Street Beacon (NASDAQ:CORT)
wsbeacon.com - January 30 at 10:18 PM
News IconCorcept Therapeutics Incorporated (CORT) Releases Earnings ... - Highland Mirror (NASDAQ:CORT)
www.highlandmirror.com - January 30 at 10:18 PM
us.rd.yahoo.com logoCorcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance (NASDAQ:CORT)
us.rd.yahoo.com - January 30 at 5:17 PM
News IconStocks Wilt on Friday But Pull Off Positive Week, How Did This One Fare: Corcept Therapeutics Incorporated (NASDAQ ... - Wall Street Beacon (NASDAQ:CORT)
wsbeacon.com - January 30 at 7:35 AM
biz.yahoo.com logoPreliminary Q4 2016 Corcept Therapeutics Inc Earnings Release - After Market Close (NASDAQ:CORT)
biz.yahoo.com - January 30 at 7:35 AM
News IconChart Indicators in Focus for Corcept Therapeutics Incorporated (CORT) - Rives Journal (NASDAQ:CORT)
rivesjournal.com - January 29 at 9:31 PM
News IconWhat Are the Technicals Saying About These Shares: Corcept Therapeutics Incorporated (CORT) - Sherwood Daily (NASDAQ:CORT)
sherwooddaily.com - January 26 at 10:36 PM
News IconSell-side Taking Aim at Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Aiken Advocate (NASDAQ:CORT)
aikenadvocate.com - January 26 at 5:34 PM
News IconEarnings in Full Force, Analysts Take Aim at Corcept Therapeutics Incorporated (NASDAQ:CORT) - Wall Street Beacon (NASDAQ:CORT)
wsbeacon.com - January 25 at 10:46 PM
bizjournals.com logoResearch Reports Coverage on Biotech Stocks -- PharmAthene, Corcept Therapeutics, Navidea Biopharma, and Inotek Pharma (NASDAQ:CORT)
www.bizjournals.com - January 25 at 5:36 PM
4-traders.com logoCorcept Therapeutics : to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call (NASDAQ:CORT)
www.4-traders.com - January 23 at 4:44 PM
finance.yahoo.com logoCorcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call (NASDAQ:CORT)
finance.yahoo.com - January 23 at 4:44 PM
News IconWill The Needle Move For Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CORT)
wsbeacon.com - January 18 at 9:47 PM
investornewswire.com logoSentiments And Ratings Alert: Corcept Therapeutics Incorporated (NASDAQ:CORT) - Investor Newswire (NASDAQ:CORT)
www.investornewswire.com - January 15 at 9:21 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Corcept Therapeutics Incorporated (NASDAQ:CORT) - Wall Street Beacon (NASDAQ:CORT)
wsbeacon.com - January 15 at 9:21 PM
News IconCorcept Therapeutics Inc CORT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CORT)
www.bioportfolio.com - January 15 at 4:21 PM
capitalcube.com logoCorcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : January 11, 2017 (NASDAQ:CORT)
www.capitalcube.com - January 11 at 4:52 PM
investornewswire.com logoCorcept Therapeutics Incorporated (NASDAQ:CORT) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:CORT)
www.investornewswire.com - December 31 at 3:10 AM
capitalcube.com logoCorcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : December 23, 2016 (NASDAQ:CORT)
www.capitalcube.com - December 23 at 4:38 PM
capitalcube.com logoCorcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : December 22, 2016 (NASDAQ:CORT)
www.capitalcube.com - December 22 at 4:36 PM
News IconEnterprise Value Review for Corcept Therapeutics Incorporated (NASDAQ:CORT) - Wall Street Beacon (NASDAQ:CORT)
wsbeacon.com - December 21 at 10:09 PM
News IconInteresting CORT Put And Call Options For August 2017 (NASDAQ:CORT)
www.stockoptionschannel.com - December 21 at 5:08 PM
News IconResearch Reports Coverage on Biotech Stocks -- Idera Pharma, bluebird bio, Corcept Therapeutics, and PhaseRx (NASDAQ:CORT)
www.kait8.com - December 16 at 4:52 PM
us.rd.yahoo.com logo4:13 pm Corcept Therapeutics: Longitude Capital lowers active stake to 10.29% following recent sale of approximately 756k shares (NASDAQ:CORT)
us.rd.yahoo.com - December 15 at 9:51 PM
News IconCompany in Focus: Corcept Therapeutics Incorporated (NASDAQ:CORT) - Business Daily Leader (NASDAQ:CORT)
businessdailyleader.com - December 12 at 4:42 PM
finance.yahoo.com logo3:37 am Corcept Therapeutics reports data from Phase 1/2 tria of Mifepristone Plus Eribulin; demonstrates encouraging results in triple-negative breast cancer (NASDAQ:CORT)
finance.yahoo.com - December 12 at 12:21 PM
finance.yahoo.com logoCorcept Korlym Positive in Phase I/II Breast Cancer Study (NASDAQ:CORT)
finance.yahoo.com - December 12 at 12:21 PM
nasdaq.com logoCorcept: Mifepristone Plus Eribulin Phase 1/2 Trial Trial Results Encouraging (NASDAQ:CORT)
www.nasdaq.com - December 11 at 11:30 AM
News IconShould You Add Corcept Therapeutics Incorporated (CORT) To Your Portfolio? (NASDAQ:CORT)
feedproxy.google.com - December 10 at 10:57 PM
News IconCorcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer (NASDAQ:CORT)
www.pressreleasepoint.com - December 10 at 4:23 PM
investingnews.com logoCymaBay Announces the Appointments of Robert Booth and Caroline Loewy to Its Board of Directors (NASDAQ:CORT)
investingnews.com - December 8 at 9:21 PM
News IconTrading Scope: Checking on Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - The Business Journal (NASDAQ:CORT)
belmontbusinessjournal.com - December 8 at 4:17 PM
News IconInvestor Watch: Checking in on Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - The Business Journal (NASDAQ:CORT)
belmontbusinessjournal.com - November 30 at 4:31 PM
News IconEquity Focus: Looking at Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Marion Business Daily (NASDAQ:CORT)
marionbusinessdaily.com - November 21 at 4:37 PM
News IconValue Composite Score Update on Corcept Therapeutics Incorporated (NASDAQ:CORT) - Wall Street Lion (NASDAQ:CORT)
wslnews.com - November 16 at 4:26 PM
News IconWhat Do Analysts Think Of Corcept Therapeutics Incorporated (CORT)? (NASDAQ:CORT)
larampadinapoli.com - November 12 at 11:38 AM
News IconTrading Focus: Eye on Shares of Corcept Therapeutics Incorporated (CORT) - MicroCap Wired (NASDAQ:CORT)
www.microcapwired.com - November 10 at 12:45 PM
News IconInsider Activity: Corcept Therapeutics Incorporated (NASDAQ:CORT)'s CHIEF EXECUTIVE OFFICER Joseph Belanoff ... - Thorold News (NASDAQ:CORT)
www.whatsonthorold.com - November 10 at 12:45 PM
finance.yahoo.com logoCORCEPT THERAPEUTICS INC Financials (NASDAQ:CORT)
finance.yahoo.com - November 5 at 4:28 PM

Social

What is Corcept Therapeutics Incorporated's stock symbol?

Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."

Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?

4 brokerages have issued 12-month price targets for Corcept Therapeutics Incorporated's stock. Their forecasts range from $7.00 to $14.00. On average, they expect Corcept Therapeutics Incorporated's stock price to reach $11.25 in the next twelve months.

When will Corcept Therapeutics Incorporated announce their earnings?

Corcept Therapeutics Incorporated is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Corcept Therapeutics Incorporated stock?

Here are some recent quotes from research analysts about Corcept Therapeutics Incorporated stock:

  • According to Zacks Investment Research, "Corcept announced preliminary results for the fourth quarter 2016 and the full year 2016. The fourth quarter results were almost in line with the Zacks Consensus Estimates while the full year results were short of the Zacks Consensus Estimates. Corcept’s share price movement shows that the stock has underperformed the Zacks classified Medical-Drugs industry in the last 3 months. Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will largely hinder the company’s growth prospects. Although Corcept is working on developing additional candidates, these compounds are still years away from commercialization. Corcept is evaluating its most advanced candidate CORT125134 in a phase I/II study to treat patients with solid-tumor cancers.  However, Corcept’s efforts to expand Korlym’s label are encouraging. Label expansion should boost the drug’s commercial potential significantly." (2/2/2017)

  • FBR & Co analysts commented, "We recently had an opportunity to host investor meetings with Corcept’s CEO, Joseph Belanoff, MD. During the meetings, investors were focused on the Korlym business, which has continued to achieve strong sales growth year over year, and Corcept’s additional pipeline candidates. As a reminder, Korlym (mifepristone) is a glucocorticoid receptor (GR) antagonist approved for the treatment of Cushing’s syndrome. We took a look at the road ahead for Corcept in 2016 and provide four key takeaways: (1) we believe the Korlym business has significant untapped growth remaining; (2) second generation GR antagonist CORT125134 remains underappreciated by the Street in our opinion; (3) mTNBC continues to be a major potential catalyst for the stock; and (4) we expect to see exciting additional programs emerge from the pipeline, given Corcept’s approximately 30 ongoing investigator- sponsored trials (ISTs). Overall, we left the meetings more confident in Corcept’s efforts across the Korlym business and development pipeline and look forward to incremental mTNBC data expected at the American Society of Clinical Oncology (ASCO) meeting in June." (4/27/2016)

Who owns Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Federated Investors Inc. PA (12.50%), Renaissance Technologies LLC (1.36%), State Street Corp (1.13%), Two Sigma Investments LP (0.55%), Menta Capital LLC (0.41%) and GSA Capital Partners LLP (0.34%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, James N Wilson, Joseph C Cook Jr, Joseph K Belanoff, Patrick G Enright and Steven Lo.

Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., GABELLI & Co INVESTMENT ADVISERS INC., Cadence Capital Management LLC, Allianz Asset Management AG, Metropolitan Life Insurance Co. NY, GSA Capital Partners LLP, Federated Investors Inc. PA and Guggenheim Capital LLC. Company insiders that have sold Corcept Therapeutics Incorporated stock in the last year include James N Wilson, Joseph K Belanoff and Patrick G Enright.

Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Investments LP, Bogle Investment Management L P DE, Russell Investments Group Ltd., Intellectus Partners LLC, Oxford Asset Management, Dimensional Fund Advisors LP and Credit Agricole S A.

How do I buy Corcept Therapeutics Incorporated stock?

Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Corcept Therapeutics Incorporated stock cost?

One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $8.30.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Earnings History Chart

Earnings by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Dividend History Chart

Dividend Payments by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)

Last Updated on 2/21/2017 by MarketBeat.com Staff